OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: New York University

8 Projects | 6 Researchers | $844,214 Invested

2016

New York University

Thomas Franke, MD, PhD

Targeting Ca2+ dysregulation in Alzheimer's Disease

  • Funding Amount: $22,930
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Calcium Regulation
  • Status: Closed

2013

New York University

Els Fieremans, PhD

White matter involvement in preclinical AD: a multimodal MR-PET study

  • Funding Amount: $200,184
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Closed

2011

New York University

Thomas Wisniewski, MD

Development of peptidomimetic ApoE/Aß Binding Inhibitors as an Effective and Non-toxic Therapeutic Approach for AD

  • Funding Amount: $100,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2011

New York University

Els Fieremans, PhD

Axonal Density as a Non-Invasive Biomarker for the Early Prediction and Monitoring of Alzheimer's Disease: an MRI Pilot Study

  • Funding Amount: $61,100
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Closed

2009

New York University

Einar Sigurdsson, PhD

Passive Immunotherapy for Frontotemporal Dementia

  • Funding Amount: $100,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2007

New York University

Einar Sigurdsson, PhD

Clearance of Pathological Tau Conformers

  • Funding Amount: $125,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2003

New York University

Joseph Helpern, PhD

High Field (3T) MRI Assessment of the Biophysical Environment of the Alzheimer's Brain

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

1999

New York University

Mony deLeon, EdD

MRI and CSF tau Protein Levels: An Early Screening Test for Alzheimer's Disease

  • Funding Amount: $85,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed